[go: up one dir, main page]

KR810001299B1 - Process for producing of 2-amino tetralin derivatives - Google Patents

Process for producing of 2-amino tetralin derivatives Download PDF

Info

Publication number
KR810001299B1
KR810001299B1 KR7803463A KR780003463A KR810001299B1 KR 810001299 B1 KR810001299 B1 KR 810001299B1 KR 7803463 A KR7803463 A KR 7803463A KR 780003463 A KR780003463 A KR 780003463A KR 810001299 B1 KR810001299 B1 KR 810001299B1
Authority
KR
South Korea
Prior art keywords
tetrahydro
ethyl
methoxy
naphthylamine
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR7803463A
Other languages
Korean (ko)
Inventor
스미로 이소다
무네후미 가나오
요시부미 이찌가와
다께시 하시즈메
기요시 이리에
요시오 가사이
Original Assignee
미야다께 가즈오
다이이찌 세이야꾸 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미야다께 가즈오, 다이이찌 세이야꾸 가부시끼 가이샤 filed Critical 미야다께 가즈오
Priority to KR7803463A priority Critical patent/KR810001299B1/en
Application granted granted Critical
Publication of KR810001299B1 publication Critical patent/KR810001299B1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음.No content.

Description

2-아미노테트라린 유도체의 제조방법Method for preparing 2-aminotetrarin derivative

본 발명은 우수한 진경(鎭痙)작용을 갖는 다음 구조식(1)의 2-아미노테트라린 유도체의 제조방법에 관한 것이다.The present invention relates to a process for the preparation of 2-aminotetrarin derivatives of the following formula (1) having excellent hardening action.

Figure kpo00001
Figure kpo00001

상기 구조식에서In the above structural formula

R1및 R2는 같거나 다른 수소원자, 저급알콕시기 또는 두개가 함께 결합하여 저급알킬렌디옥시기를 나타내며,R 1 and R 2 are the same or different hydrogen atoms, lower alkoxy groups or two bonded together to represent a lower alkylenedioxy group,

R3는 수소원자, 저급알킬기 또는 사이클로알킬기를 나타내며,R 3 represents a hydrogen atom, a lower alkyl group or a cycloalkyl group,

R4, R5, R6는 같거나 다른 수소원자, 저급알콕시기, 저급알킬기, 할로겐기, 수사기 또는 두 개가 함께 결합하여 저급알킬렌디옥시기를 나타내며,R 4 , R 5 , R 6 represent the same or different hydrogen atom, lower alkoxy group, lower alkyl group, halogen group, investigating group or two together to form a lower alkylenedioxy group,

A는 직쇄 또는 측쇄의 탄소수 2 내지 10개를 갖는 알킬렌기 또는 중간에 산소원자로 에테르결합을 갖는 알킬렌기를 나타낸다.A represents a linear or branched alkylene group having 2 to 10 carbon atoms or an alkylene group having an ether bond as an oxygen atom in the middle.

본 발명의 2-아미노테트라린 유도체로서 예를 들면 다음과 같은 것을 들 수가 있으며, 또한 각 화합물의 유리형(遊離型)의 것 밑 기타의 산부가염류도 본 발명에 포함된다.Examples of the 2-aminotetrarin derivative of the present invention include the following compounds, and other acid addition salts below the free form of each compound are also included in the present invention.

(1)N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부티르]-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 "화합물 A"로 기술).(1) N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyr] -1,2,3,4-tetrahydro-2-naphthylamine hydrochloride (hereinafter referred to as compound A) Technology).

(2)N-에틸-N-[6-(3,4-디메톡시벤조일옥시)헥실]-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 "화합물 B"로 기술).(2) N-ethyl-N- [6- (3,4-dimethoxybenzoyloxy) hexyl] -1,2,3,4-tetrahydro-2-naphthylamine hydrochloride (hereinafter referred to as "Compound B" ).

(3)N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-5-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(3) N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -5-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(4)N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(4) N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(5)N-에틸-N-[2-(3,4-디메톡시벤조일옥시)에틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(5) N-ethyl-N- [2- (3,4-dimethoxybenzoyloxy) ethyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(6)N-메틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(6) N-methyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(7)N-에틸-N-[3-(3,4-디메톡시벤조일옥시)프로필]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(7) N-ethyl-N- [3- (3,4-dimethoxybenzoyloxy) propyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(8)N-에틸-N-[3-(3,4-디메톡시벤조일옥시)-2,2-디메틸프로필]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(8) N-ethyl-N- [3- (3,4-dimethoxybenzoyloxy) -2,2-dimethylpropyl] -6-methoxy-1,2,3,4-tetrahydro-2-naph Thiaminel Hydrochloride

(9)N-에틸-N-[2-(2-(3,4-디메톡시벤조일옥시)에톡시]에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(9) N-ethyl-N- [2- (2- (3,4-dimethoxybenzoyloxy) ethoxy] ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthyl Amine hydrochloride

(10)N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 "화합물 C"로 기술).(10) N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride (hereinafter " As compound CVII).

(11)N-에틸-N-[4-(벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(11) N-ethyl-N- [4- (benzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(12)N-에틸-N-[4-(3,4-디하이드록벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(12) N-ethyl-N- [4- (3,4-dihydroxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(13)N-산염-N-(4-(4-에틸메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(13) N-salt-N- (4- (4-ethylmethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(14)N-에틸-N-[4-(3-메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(14) N-ethyl-N- [4- (3-methoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(15)N-에틸-N-[4-(4-에톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(15) N-ethyl-N- [4- (4-ethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(16)N-에틸-N-[4-(4-프로폭시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(16) N-ethyl-N- [4- (4-propoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(17)N-에틸-N-[4-(4-메틸벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(17) N-ethyl-N- [4- (4-methylbenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(18)N-에틸-N-[4-(3-메톡시-4-에톡시-벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(18) N-ethyl-N- [4- (3-methoxy-4-ethoxy-benzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine Hydrochloride

(19)N-에틸-N-[4-(3,4-디클로로벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(19) N-ethyl-N- [4- (3,4-dichlorobenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(20)N-에틸-N-[4-(3,4-메틸렌옥시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(20) N-ethyl-N- [4- (3,4-methyleneoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(21)N-에틸-N-[4-(2,6-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(21) N-ethyl-N- [4- (2,6-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(22)N-에틸-N-[4-(3,4,5-트리메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민설폰산염(22) N-ethyl-N- [4- (3,4,5-trimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylaminesulfone Acid

(23)N-에틸-N-[4-(3,4,5-트리에톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(23) N-ethyl-N- [4- (3,4,5-triethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(24)N-에틸-N-[6-(3,4-디메톡시벤조일옥시)헥실]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 "화합물 D"로 기술).(24) N-ethyl-N- [6- (3,4-dimethoxybenzoyloxy) hexyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride (hereinafter referred to as As compound D ').

(25)N-에틸-N-[8-(3,4-디메톡시벤조일옥시)옥틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(25) N-ethyl-N- [8- (3,4-dimethoxybenzoyloxy) octyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(26)N-에틸-N-[10-(3,4-디메톡시벤조일옥시)데실]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(26) N-ethyl-N- [10- (3,4-dimethoxybenzoyloxy) decyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(27)N-벤조일옥시-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 "화합물 E"로 기술).(27) N-benzoyloxy-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride (hereinafter referred to as Described as "Compound E").

(28)N-이소프로필-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 "화합물 L"로 기술).(28) N-isopropyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride (hereinafter referred to as 기술 Compound L ").

(29)N-사이클로헥실-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(29) N-cyclohexyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(30)N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-에톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(30) N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-ethoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(31)N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-프로폭시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(31) N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-propoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(32)N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-5,8-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(32) N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -5,8-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(33)N-에틸-N-4-(3,4-디메톡시벤조일옥시)부틸]-6,7-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 "화합물 F"로 기술).(33) N-ethyl-N-4- (3,4-dimethoxybenzoyloxy) butyl] -6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride (hereinafter referred to as Described as "Compound F").

(34)N-에틸-N-[6-(3,4-디메톡시벤조일옥시)헥실]-6,7-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 '"화합물 G"로 기술).(34) N-ethyl-N- [6- (3,4-dimethoxybenzoyloxy) hexyl] -6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride ( Hereinafter referred to as 'Compound G').

(35)N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6,7-메틸렌디옥시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(35) N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6,7-methylenedioxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(36)N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-7-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 "화합물 H"로 기술).(36) N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -7-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride (hereinafter As compound H ′).

(37)N-에틸-N-[4-(4-(3,4-디메톡시벤조일옥시)부틸]-8-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(이하 "화합물 K"로 기술).(37) N-ethyl-N- [4- (4- (3,4-dimethoxybenzoyloxy) butyl] -8-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride (Hereinafter referred to as compound K).

(38)N-에틸-N-[6-(3,4-디메톡시벤조일옥시)헥실]-8-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(38) N-ethyl-N- [6- (3,4-dimethoxybenzoyloxy) hexyl] -8-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(39)N-에틸-N-[4-(4-메틸벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(39) N-ethyl-N- [4- (4-methylbenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

(40)N-에틸-N-[4-(3,4-디클로로벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염(40) N-ethyl-N- [4- (3,4-dichlorobenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride

상술한 본 발명의 2-아미노테트라린 유도체는 여러가지 방법에 의하여 제조할 수 있으나 대표적인 방법으로는 다음 구조식(II)의 화합물과 다음 구조식(III)의 화합물을 탄산나트륨 또는 무수탄산칼슘과 같은 염기존재하에 아세톤, 메틸에틸케톤, 아세트니트릴벤젠과 같은 구조식(II) 및 구조식(III)과 반응하지 않는 통상의 유기용매중에서 가열하므로서 구조식(I)의 2-아미노테트라진 유도체를 수득할 수 있다.The 2-aminotetrarin derivatives of the present invention described above can be prepared by various methods, but representative methods include compounds of the following formula (II) and compounds of the following formula (III) in the presence of a base such as sodium carbonate or anhydrous calcium carbonate. 2-aminotetrazine derivatives of formula (I) can be obtained by heating in conventional organic solvents that do not react with formulas (II) and (III) such as acetone, methyl ethyl ketone, acetonitrile benzene.

Figure kpo00002
Figure kpo00002

상기 구조식에서In the above structural formula

R1, R2및 R3는 상기 정의한 바와 같으며,R 1 , R 2 and R 3 are as defined above,

R4, R5, R6는 수산기를 제외한 상기 정의한 바와 같으며,R 4 , R 5 , R 6 are as defined above except for hydroxyl groups,

A는 상기 정의한 바와 같으며, 및A is as defined above, and

X는 할로겐 원자를 나타낸다.X represents a halogen atom.

이때 X가 요드이외의 할로겐원자일 경우에는 요드화 나트륨을 가하므로서 반응을 원활하게 진행시킬 수가 있다.In this case, when X is a halogen atom other than iodine, the reaction can proceed smoothly by adding sodium iodide.

또한, 구조식(II)의 화합물과 다음 구조식(IV)의 화합물을 트리에틸아민, 트리메틸아민등의 염기와 같이 벤젠, 톨루엔, 크실렌, 클로로포름등의 구조식(II) 및 구조식(IV)와 반응하지 않는 통상의 유기용매중에 반응시키고, 다음 구조식(V)의 화합물을 합성한 다음 구조식(V)의 화합물을 에테르, 테트라하이드로푸란, 디옥산등의 유기용매중에 수소화 리티움알미늄과 반응시켜서 다음 구조식(VI)의 화합물을 합성한다. 상기 구조식(VI)의 화합물을 다음 구조식(VII)의 화합물과 트리에틸아민, 트리메틸아민등의 염기존재하에 또는 존재하지 않는데에서 벤젠, 톨루엔, 크실렌, 클로로포름등의 구조식 (VI) 및 (VII)과 반응하지 않는 통상의 유기용매중에서 반응시켜 구조식(I)의 2-아미노테트라린 유도체를 수득할 수 있다.In addition, the compound of formula (II) and the following formula (IV) do not react with the formulas (II) and (IV) such as benzene, toluene, xylene, chloroform, and the like as bases such as triethylamine and trimethylamine. After reacting in a conventional organic solvent, the compound of formula (V) is synthesized, and then the compound of formula (V) is reacted with lithium hydride aluminum in an organic solvent such as ether, tetrahydrofuran, dioxane, and the like. To synthesize a compound. The compound of formula (VI) is represented by the following formulas (VI) and (VII), such as benzene, toluene, xylene, chloroform, in the presence or absence of a base of the compound of formula (VII) and triethylamine, trimethylamine, etc. The reaction can be carried out in a conventional organic solvent which does not react to obtain 2-aminotetrarin derivative of formula (I).

Figure kpo00003
Figure kpo00003

상기 구조식에서In the above structural formula

R7는 저급알킬렌기를 나타내며,R 7 represents a lower alkylene group,

B는 A보다 탄소수가 두개 적은 알킬렌기를 나타낸다.B represents an alkylene group having two carbon atoms less than A.

Figure kpo00004
Figure kpo00004

상기 구조식에서In the above structural formula

R1, R2, R3, R7, B는 상기 정의한 바와 같다.R 1 , R 2 , R 3 , R 7 and B are as defined above.

Figure kpo00005
Figure kpo00005

상기 구조식에서In the above structural formula

R1, R2, R3는 상기 정의한 바와 같다.R 1 , R 2 and R 3 are as defined above.

Figure kpo00006
Figure kpo00006

상기 구조식에서In the above structural formula

X 및 R4, R5, R6는 수산기인 것을 제외한 상기 정의한 바와 같다.X and R 4 , R 5 and R 6 are as defined above except that they are hydroxyl groups.

또 R4, R5및 R6가 수산기인 구조식(I)의 화합물을 수득할 경우에는 원료화합물(III) 또는 (VII)의 수산기를 벤질기등의 보호기로 보호한후 상기의 제조방법에 따라 제조를 행하고 최후에 보호기를 접촉환원등에 에스테르기의 절단을 수반하지 않는 방법으로 분리시키면 된다.In the case of obtaining a compound of formula (I) wherein R 4 , R 5 and R 6 are hydroxyl groups, the hydroxyl group of the starting compound (III) or (VII) is protected with a protecting group such as benzyl group, and then What is necessary is just to carry out manufacture, and finally, a protecting group is isolate | separated by the method which does not involve cutting | disconnection of ester group in contact reduction etc.

또한 구조식(I)은 산부가염을 형성시킬 수가 있으며, 이산으로서는 염산, 취화수소산, 황산, 인산, 질산등의 무기산과 주석산, 구연산, 메탄술폰산, P-톨루엔술폰산, 수산, 주석산, 구연산, 메탄술폰산, -톨루엔술폰산, 수산, 유산, 능금산, 말레산등의 유기산등의 유기산을 들 수 있다.In addition, the structural formula (I) can form acid addition salts, and as diacids, inorganic acids such as hydrochloric acid, hydrous acid, sulfuric acid, phosphoric acid, nitric acid, tartaric acid, citric acid, methanesulfonic acid, P-toluenesulfonic acid, hydroxyl acid, tartaric acid, citric acid, methanesulfonic acid And organic acids such as organic acids such as -toluenesulfonic acid, fisheries, lactic acid, nitric acid and maleic acid.

다음에 본 발명의 화합물의 유용성에 대하여 상술한다.Next, the usefulness of the compound of this invention is explained in full detail.

본 발명의 2-아미노테트라린유도체는 위, 장관(腸管)등의 평활근장기(平滑筋臟器)에 대하여 우수한 진경작용을 나타내며, 특히 하부소화관(下部消化管)에 대하여 현저한 진경작용을 발휘하는 의약으로써 매우 유용한 화합물이다. 다음 표 1은 개 생체위(生體位)의 골반신경자극에 의한 결장(結腸)운동에 대한 작용을 본 발명의 대표적 화합물에 대하여 연구한 실험결과이다. 또 하부소화관에 대한 진경약으로서 공지되어 있는 기지 화합물 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-3-(4-메톡시페닐)-2-프로필아민염산염(이하 "메베베린"이라고 기술)을 대조하였다.The 2-aminotetrarin derivative of the present invention exhibits excellent mycelial action against smooth muscle organs such as stomach and intestinal tract, and especially exhibits significant mycelial action against the lower digestive tract. It is a very useful compound as a medicine. Table 1 below shows the results of studies on the representative compounds of the present invention on the effects of colon movement by pelvic nerve stimulation on the dog's biological stomach. Also known compound N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -3- (4-methoxyphenyl) -2-propylamine hydrochloride, known as an antifungal for the lower digestive tract. (Hereinafter, referred to as “mebeberine”).

[표 1]TABLE 1

Figure kpo00007
Figure kpo00007

또 상기 표 1의 실험에는 일반적으로 밸룬(Balloon) 법이는 일컫는 방법을 사용하였으나 상세한 것은 다음과 같다.In addition, in the experiment of Table 1, a ballon method is generally used, but the method is called as follows.

개생체위의 골신경자극에 의한 결장운동에 대한 작용의 실험방법(Balloon 법). 체중 8 내지 15kg의 잡종견을 암컷 및 수컷의 구별없이 사용하였다.Experimental method of colonic motion due to bone nerve stimulation on dog body (Balloon method). Mongrel dogs weighing 8-15 kg were used without distinction between females and males.

밸트발비털 30mg/kg 정맥에 투여하여 마취한 후 배위(背位)에 고정하고, 하복부중심선을 따라 개복하고 물을 채운 고무공을 홍문으로부터 하행결장(下行結腸)에 삽입하고 고정한 후 각화합물의 100㎍/kg를 정맥내 주사에 의하여 투여하여 내압의 변화를 저압용 트랜스듀서를 개재하여 프마그래프로 기록하였다. 골반신경의 자극조건으로 빈도 : 50cps, 지속시간 : 1msec, 전압 : 4V의 단형파로 5초간 전기자극하고 이것을 3분마다 반복하였다.Belt Valbital Hair 30mg / kg Intravenous anesthesia, anesthetized, fixed to the stomach, and open to the lower abdomen central line and water-filled rubber ball from hongmun to descending colon and fixed and fixed 100 Μg / kg was administered by intravenous injection, and the change in the internal pressure was recorded in a graphagram through a low pressure transducer. The stimulation conditions of the pelvic nerve were electrical stimulation with a short wave of frequency: 50 cps, duration: 1 msec, and voltage: 4 V for 5 seconds.

억제율은 다음식에 의하여 산출하였다.Inhibition rate was calculated by the following equation.

Figure kpo00008
Figure kpo00008

또한, 다음 표 2는 본 발명의 대표적 화합물의 쥐에 대한 독성과 쥐 생체위의 네오티그민자극에 의한 결장운동에 대한 작용을 검토하고 그안적역을 메베베린을 대조로하여 연구한 결과이다.In addition, Table 2 shows the results of studies on the toxicity of the representative compounds of the present invention to the colon movement by neo-tigmin stimulation of rats in rats and the mesothelioma in contrast to mebeberin.

[표 2]TABLE 2

Figure kpo00009
Figure kpo00009

또 표 2의 실험조작의 상세한 것은 다음과 같다.The details of the experimental operation of Table 2 are as follows.

쥐생체위의 네오스티그민자극에 의한 결장운동에 대한 작용의 실험방법 (Balloon 법).Experimental method of colonic movement by neostigmine stimulation on rat living body (Balloon method).

체중 300 내지 400g의 STD-wistar 종 숫컷의 쥐를 사용하였다. 쥐를 우레탄 1g/kgip로 마취한후 배위에 고정하고, 물을 체운 고무공을 홍문으로부터 하행결장에 삽입 고정하여 내압의 변화를 저압용 트랜스듀서를 통하여 포리그래프로 기록하였다.Mice of male STD-wistar species weighing 300-400 g were used. Rats were anesthetized with 1 g / kgip of urethane and fixed to the stomach, and a rubber ball filled with water was inserted and fixed from the hongmun to the descending colon, and the change in internal pressure was recorded in a polygraph through a low pressure transducer.

일정하게 결장운동을 장시간 지속시키기 위하여 네오스티그민을 90㎍/kg/hr의 속도로 피하에 지속 주입하였다. 또 약물은 경구의 증류수에 녹이고 경구카테텔을 통하여 0.2ml/100g의 율로 위내에 주입하였다. ED50는 사용동물중의 50%의 개체(個體)에 있어서 작용을 발현하는 투여량으로 표시하였다.Neostigmine was continuously injected subcutaneously at a rate of 90 µg / kg / hr to maintain constant colon exercise for a long time. In addition, the drug was dissolved in oral distilled water and injected into the stomach at the rate of 0.2ml / 100g through oral cathetel. ED 50 was expressed as the dose which expresses the action in 50% of the animals in use.

이상 상기 표 1 및 표 2에서 본 발명의 화합물은 우수한 진경작용을 가지며 또한 저독성(低毒性)이 있으며, 의약으로써 유용하다는 것이 이미 명백하지만 또 다른 관점에서 본 발명화합물의 특성을 하기에 기술하였다.In the above Table 1 and Table 2, the compound of the present invention has excellent antifungal action, is also low toxicity, and it is already clear that it is useful as a medicament.

종래의 항코린작동성 진경약은 위 장관에 대하여서는 상부하부의 구별없이 작용하지만 본 발명 화합물은 특히 하부소화관에 대하여 선택성이 있는 진경작용을 나타낸다. 다음 표 3은 본 발명의 대표적 화합물에 대하여 개의 미주신경(迷走神經) 전기자극에 대한 위의 수축운동의 50% 억제필요량(S, ID50)과 개의 골반신경전기적자극에 대한 결장의 수축운동의 50% 억제필요량(C, ID50)를 구하고 그 비에 따라 진경작용의 선택성을 연구한 것이다. 또 비교하여 사용된 메베베린도 하부소화관에 대하여 선택성이 있는 진경작용을 나타내는 약물로 하고 있다.Conventional anticholinergic antifungal drugs act without distinction of the upper and lower part for the gastrointestinal tract, but the compounds of the present invention exhibit selective selective myocardial action for the lower digestive tract. Table 3 below shows the 50% inhibition of gastric contraction (S, ID 50 ) and 50 colonic contractile movements of the dog's pelvic nerve stimulation for dog vagus nerve stimulation. The percent inhibition required (C, ID 50 ) was obtained and the selectivity of mycelial action was studied according to the ratio. In addition, Mebeberin used in comparison with the lower digestive tract is a drug that exhibits a selective mycelial action.

다음 표 3에서 명백한 바와 같이 본 발명의 대표적화합물은 메베베린보다도 우수한 선택성을 가지고 있다.As is apparent from the following Table 3, the representative compound of the present invention has superior selectivity to mebeberine.

[표 3]TABLE 3

Figure kpo00010
Figure kpo00010

또 상기 표 3의 S, ID50을 구하는 실험은 다음의 조작법에 의한 것이다.Further experiments to obtain the above Table 3, S, ID 50 is obtained from the following Instruction of.

체중 8 내지 15kg의 잡종견을 임컷 및 수컷의 구별없이 사용하였다.Mongrel dogs weighing 8-15 kg were used without discrimination between the male and the male.

펜토바르비탈륨 30mg/kg 정맥내 투여에 의하여 마취한 후 배위에 고정하고 상복부중심선에 따라 절개하고 위의 위체부(胃體部)대만축을 절개하고 물을 채운 고무공을 삽입하고 내압의 변화를 저압용 트랜듀서를 계재하여 포리그래프로 기록하였다. 미주신경의 자극조건으로서 빈도 : 20cps, 지속시간 : 1m sec, 전압 : 8V의 단형파로 10초간 전기자극하고 이것을 3분마다 반복하였다.After anesthesia by pentobarbitalum 30mg / kg intravenous administration, fixation to stomach, incision along central epigastric line, incision of upper gastrointestinal axial axis, insertion of rubber ball filled with water and change of internal pressure for low pressure Transducers were recorded and recorded as polygraphs. As a stimulating condition of the vagus nerve, a short wave of frequency: 20 cps, duration: 1 m sec, and voltage: 8 V was electrically stimulated for 10 seconds and repeated every 3 minutes.

억제율(%)은 다음 식에 의해서 산출하고 S, ID 50은 50%억제율을 표시할때의 투여량으로 하였다.Inhibition rate (%) was calculated by the following formula, and S, ID 50 was the dose when the 50% inhibition rate was indicated.

Figure kpo00011
Figure kpo00011

또, C, ID50의 치는 표 1의 경우와 같은 실험조작(약물 투여량을 변경할 수 있다)에 의하여 얻어진 실험 데이타에서 50% 억제율을 표시할때의 투여량으로 하였다.In addition, and at a dose of time to display a 50% inhibition in the experimental data obtained by the experimental manipulations (which can change the drug dose), such as in the case of Table 1, values of C, ID 50.

또 상기 표 1 및 표 3에 관한 실험방법은 기지의 방법에 준한 것이다(European Journal of Pharmacology 18(1972) page 1 내지 14에 기록).In addition, the experimental method with respect to Table 1 and Table 3 is based on the known method (recorded in pages 1 to 14 of the European Journal of Pharmacology 18 (1972)).

다음 실시예에 의하여 본 발명을 설명하였다.The invention is illustrated by the following examples.

[실시예 1]Example 1

N-에틸-1,2,3,4-테트라하이드로-2-나프틸아민 1.85g, 3,4-디메톡시안식향산-4-요드화부틸에스테르 3.9g, 탄산소다 1.1g, 및 메틸에틸 케톤 40ml를 혼합하고 60시간 가열하여 환류한다. 반응액을 감압하에 농축하고 잔사에 물을 가하고 클로로포름으로 추출한다. 클로로포름층을 수세하고 무수유산 나트륨으로 건조후 감압하에 농축하고 잔류하는 유상물을 실리카겔크로마토그라피에 의하여 정제한다. 여기에 염화수소, 에탄올용액을 가하여 감압하에 농축한다. 아세톤 에테르혼액으로부터 결정화사켜 석출한 결정을 여과하고 알콜, 에테르로부터 재결정하면 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색분말 2. 3g를 얻었다.1.85 g of N-ethyl-1,2,3,4-tetrahydro-2-naphthylamine, 3.9 g of 3,4-dimethoxybenzoic acid-4- iodide butyl ester, 1.1 g of sodium carbonate, and 40 ml of methyl ethyl ketone Are mixed and heated to reflux for 60 hours. The reaction solution is concentrated under reduced pressure, water is added to the residue, and the mixture is extracted with chloroform. The chloroform layer is washed with water, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the remaining oil is purified by silica gel chromatography. Hydrogen chloride and ethanol solution were added thereto, and it concentrated under reduced pressure. Crystallized crystallized from acetone ether mixture and filtered and recrystallized from alcohol and ether, N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -1,2,3,4-tetra Colorless powder of hydro-2-naphthylamine hydrochloride 2. 3 g was obtained.

Figure kpo00012
Figure kpo00012

[실시예 2]Example 2

(가) 6-메톡시-2-테트라론 28.0g, 19% 에틸아민에탄올용액 200ml, 산화백금 2, 2g, 무수에탄올 10ml를 혼합하고 외부로부터 적외선램프로 조사(照射)하여 접촉환원을 행한다. 수소를 흡수한후 여과하여 촉매를 제거하고 여액을 감압하에 농축하고 잔사를 클로로포름으로 유출한다. 클로로포름층을 수세, 무수유산나트륨으로 건조후감압하에 농축한다.(A) 28.0 g of 6-methoxy-2-tetraron, 200 ml of 19% ethylamine ethanol solution, 2, 2 g of platinum oxide, and 10 ml of anhydrous ethanol are mixed and irradiated with an infrared lamp from the outside to carry out contact reduction. After absorbing hydrogen, the catalyst was removed by filtration, the filtrate was concentrated under reduced pressure, and the residue was flowed into chloroform. The chloroform layer is washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure.

잔사에 염화수소에탄올용액을 가하여 감압하에 농축한다. 잔사에 아세톤을 가하여 석출하는 결정을 여과하고 알콜, 에테르로부터 재결졍하여 N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 9.7g을 얻는다.Hydrogen chloride solution was added to the residue and concentrated under reduced pressure. Acetone was added to the residue, and the precipitated crystals were filtered and recrystallized from alcohol and ether to give 9.7 g of colorless crystals of N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride. Get

Figure kpo00013
Figure kpo00013

(나)N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 2.0 g을 2N-수산화나트륨 20ml와 혼합하고 클로로포름으로 추출한다. 클로로포름층을 건조후 감압하에 농축하여 얻어진 유리염기에 3,4-디메톡시안식 향산 4-옥타부틸에스테르 3.1g, 탄산나트륨 0.9g 및 메틸에틸테톤 40ml를 혼합하여 60시간동안 가열환류한다. 반응액을 감압하에 농축하고 잔사에 물을 가하고, 클로로포름으로 추출한다. 클로로포름층을 수세하여 무수유산나트륨으로 건조후감압하에 농축하고 잔류하는 유상(油狀)물을 실리카겔크로마토그라피로 정제하여 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민용액을 가하여 감압하에 농축한다. 잔사를 아세톤으로 용해하고 에틸을 가하고 저온으로 방치해두고 석출한 결정을 여과하여 모으고 다시 아세톤, 에테르혼합액으로부터 재결정하여 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 2.65g을 얻었다.(B) 2.0 g of N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride is mixed with 20 ml of 2N-sodium hydroxide and extracted with chloroform. The chloroform layer was dried and concentrated under reduced pressure, and 3.1 g of 3,4-dimethoxybenzoic acid 4-octabutyl ester, 0.9 g of sodium carbonate, and 40 ml of methyl ethyl tetone were mixed and heated to reflux for 60 hours. The reaction solution is concentrated under reduced pressure, water is added to the residue, and the mixture is extracted with chloroform. The chloroform layer was washed with water, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the remaining oily substance was purified by silica gel chromatography, and purified with N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl. ] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine solution is added and concentrated under reduced pressure. The residue was dissolved in acetone, ethyl was added, left at low temperature, the precipitated crystals were collected by filtration, and recrystallized from acetone and an ether mixture, which was then recrystallized from N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl]. 2.65 g of colorless crystals of -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride were obtained.

Figure kpo00014
Figure kpo00014

[실시예 3]Example 3

(가)수소화리티움알미늄 4.7g과 무수 테트라하이드로푸란 200ml을 혼합하고 여기에 N-아세틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 10g의 무수테트라하이드로푸란 100ml의 혼합액을 적가한다. 실온으로 0.5시간 교반한 후 4시간 가열환류하고 빙냉하에 물 4.7ml와 테트라하이드로푸란 50ml의 혼액을 적가한다. 계속해서 15% 수산화나트륨 4.7ml 또 물 14ml의 순으로 적가한다. 석출한 불용물을 여과하여 모으고 여액을 감압하여 농축한다. 잔사를 클로로 포름으로 추출하고 클로로포름층을 수세후 무수유산나트륨으로 건조후 감압하에 농축하고 잔류하는 유상물(油狀物)에 염화수소에탄올 용액을 가하여 감압농출한다. 아세톤을 가하여 석출한 결정을 여과하고 알콜, 에테르로부터 재결정하여 N-에틸-6-메톡시-1,2,3,4,-테트라하이드로-2-나프틸아민염산염의 무색침상정 8.9g을 수득다.(A) 4.7 g of hydrogen hydride aluminum and 200 ml of anhydrous tetrahydrofuran are mixed and 10 g of anhydrous tetrahydro of 10 g of N-acetyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine is added thereto. A mixture of 100 ml of furan is added dropwise. After stirring for 0.5 hour to room temperature, the mixture was heated to reflux for 4 hours, and a mixture of 4.7 ml of water and 50 ml of tetrahydrofuran was added dropwise under ice-cooling. Then add 4.7 ml of 15% sodium hydroxide and 14 ml of water dropwise. The precipitated insolubles are collected by filtration, and the filtrate is concentrated under reduced pressure. The residue was extracted with chloroform, washed with chloroform and dried over anhydrous sodium sulfate, concentrated under reduced pressure, and concentrated under reduced pressure by adding hydrogen ethanol solution to the remaining oil. Acetone was added, and the precipitated crystals were filtered and recrystallized from alcohol and ether to obtain 8.9 g of colorless needles of N-ethyl-6-methoxy-1,2,3,4, tetrahydro-2-naphthylamine hydrochloride. All.

융점 231 내지 232℃이 융점 및 적외흡수스펙트럼등의 물리적 모든 데이타는 실시예 2(가)에서 얻어진 것과 일치한다.All physical data, such as melting | fusing point 231-232 degreeC, melting | fusing point and an infrared absorption spectrum, are consistent with what was obtained by Example 2 (a).

(나)N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 2.0 g으로부터 통상법에 의하여 얻어진 유리염기에 3,4-디메녹시안식향산 6-클로로-헥실에스테르요 3.1g, 드화나트륨 1.4g, 탄산나트륨 2.0g 및 메틸에틸케톤 80ml을 가하여 90시간동안 가열환류한다. 반응액을 감압하에 농축하고 잔사를 클로로포름으로 추출한다.(B) 3,4-dimethoxyanic acid 6-chloro as a free base obtained by a conventional method from 2.0 g of N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride 3.1 g of hexyl ester, 1.4 g of sodium dehydrate, 2.0 g of sodium carbonate and 80 ml of methyl ethyl ketone are added and heated to reflux for 90 hours. The reaction solution is concentrated under reduced pressure and the residue is extracted with chloroform.

클로로포름층을 수세 무수유산나트롬으로 건조후 감압하에 농축하여 얻어진 유상물을 실리카겔 컬럼 크로마토 그라피 정제하여 N-에틸-N-(6-(3,4-디메톡시벤조일옥시)헥실]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 담황색유상물을 얻는다. 이것을 염화수소, 에탄올용액에 녹이고 감압하에 농축한다. 잔사를 아세톤에 용해하고 에테르를 가하고 저온에 방치하여 석출된 결정을 여과하여 모으고 아세톤, 에테르의 혼액으로부터 재결정하여 N-에틸-N-[6-(3,4-디메톡시벤조일옥시)헥실]-6-메톡시-1,2,3,4-테트라하이드로-3-나프틸아민염산염의 무색결정 119를 얻는다.The chloroform layer was dried over anhydrous sodium sulfate anhydrous and concentrated under reduced pressure. The oily substance was purified by silica gel column chromatography, and purified by N-ethyl-N- (6- (3,4-dimethoxybenzoyloxy) hexyl] -6-meth. Obtain a pale yellow oily substance of oxy-1,2,3,4-tetrahydro-2-naphthylamine, dissolve in hydrogen chloride and ethanol solution, concentrate under reduced pressure, dissolve the residue in acetone, add ether and leave at low temperature. The precipitated crystals were collected by filtration and recrystallized from a mixture of acetone and ether to give N-ethyl-N- [6- (3,4-dimethoxybenzoyloxy) hexyl] -6-methoxy-1,2,3,4- Colorless crystal 119 of tetrahydro-3-naphthylamine hydrochloride is obtained.

Figure kpo00015
Figure kpo00015

[실시예 4]Example 4

(가)무수염화알미늄 7.4g, 무수메틸렌클로라이드 100ml의 혼합액을 50℃에서 냉각하고 여기에 3,4-디메톡시페닐 초산클로라이드 5.9g과 무수메틸렌클로라이드 30ml의 용액을 적하한다. 이어서 심하게 교반하면서 에틸렌을 15분간에 걸쳐서 심하게 주입한다. 그런다음 신온으로 3시간반동안 교반한후 외부로부터 빙수로 냉각하고 물 40ml를 적하한다.(A) A mixture of 7.4 g of aluminum anhydride and 100 ml of anhydrous methylene chloride is cooled at 50 ° C, and a solution of 5.9 g of 3,4-dimethoxyphenyl acetate chloride and 30 ml of anhydrous methylene chloride is added dropwise thereto. The ethylene is then heavily injected over 15 minutes with vigorous stirring. Then, the mixture was stirred for 3 hours and a half at room temperature, cooled with ice water from the outside, and 40 ml of water was added dropwise.

에틸렌클로라이드층을 2 N-염산, 물, 포화탄산수소나트륨수, 물의 순서로 세정하고 무수유산나트륨으로 건조후 감압하여 농축하여 유상물을 수득한다. 여기에 19% 에틸아민에탄올용액 25ml, 무수에탄올 10ml 및 산화백금 0.25g을 가하여 접촉환원을 행한다. 수소흡수가 끝난후 촉매를 여과하여 제거하고 여액을 감압하에 농축하고 잔사에 염화수소, 에탄올용액을 가하고 감압하에 농축한다. 아세톤을 가하고 석출한 결정을 여과하여 모으고 2N-수산화나트륨수용액을 가하고 클로로포름으로 추출하고 수세후 무수탄산칼륨으로 건조후 감압하여 농축한다. 잔사를 알루미나 컬럼크로마토그라피로 정제한다. 여기에 염화수소, 에탄올용액을 가하여 감압하에 농축하여 얻어진 결정을 무수에탄올, 이소프로판올의 혼액으로 부터 재결정하여 N-에매-6,7-디메톡시-1,2,3,4-테트라하이드로-2-나프틸염산염의 무색침상정 1.12g을 수득하였다.The ethylene chloride layer was washed with 2N hydrochloric acid, water, saturated sodium bicarbonate water and water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain an oily substance. 25 ml of 19% ethylamine ethanol solution, 10 ml of anhydrous ethanol and 0.25 g of platinum oxide were added thereto to carry out catalytic reduction. After hydrogen absorption is completed, the catalyst is filtered off, the filtrate is concentrated under reduced pressure, hydrogen chloride and ethanol solution are added to the residue and concentrated under reduced pressure. Acetone was added, and the precipitated crystals were collected by filtration, 2N aqueous sodium hydroxide solution was added, extracted with chloroform, washed with water, dried over anhydrous potassium carbonate, and concentrated under reduced pressure. The residue is purified by alumina column chromatography. Hydrogen chloride and ethanol solution were added, and the crystal | crystallization obtained by concentrating under reduced pressure was recrystallized from the mixture of anhydrous ethanol and isopropanol, and it was N-Emeth-6,7-dimethoxy- 1,2,3,4- tetrahydro-2-naphth. 1.12 g of colorless needles of butyl hydrochloride were obtained.

Figure kpo00016
Figure kpo00016

(나)N-에틸-6,7-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산염 390ml, 3,4-디메톡시안식향산 4-클로로 부틸에스테르 500mg, 요드화나트륨 270mg, 무수탄산나트륨 200mg, 메틸에틸케논 30mg를 사용하여 실시예 3(나)에 준하여 행하고 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6,7-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 400ml를 얻는다.(B) N-ethyl-6,7-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl amine 390 ml, 3,4-dimethoxy benzoic acid 4-chloro butyl ester 500 mg, sodium iodide N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6,7-dimethoxy was carried out in accordance with Example 3 (b) using 270 mg, 200 mg of anhydrous sodium carbonate, and 30 mg of methylethylkenone. 400 ml of colorless crystals of -1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00017
Figure kpo00017

[실시예 5]Example 5

N-에틸-6,7-디메톡시-1,2,3,4-테트라하이드로나프-2-틸아민염산염 6.0 g, 3,4-디메톡시안식향산 6-클로로헥실에스테르 9.2g, 요드화나트륨 4.6g 탄산나트륨 3.3g 및 메틸에틸케톤 150ml를 사용하여 실시예 3(나)에 따라 행하고 N-에틸-N-[6-(3,4-디메톡시벤조일옥시)헥실]-6,7-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색침상정 7.0g을 수득하였다.6.0 g of N-ethyl-6,7-dimethoxy-1,2,3,4-tetrahydronaph-2-tylamine hydrochloride, 9.2 g of 3,4-dimethoxybenzoic acid 6-chlorohexyl ester, sodium iodine 4.6 g 3.3 g sodium carbonate and 150 ml of methyl ethyl ketone, were prepared according to Example 3 (b), followed by N-ethyl-N- [6- (3,4-dimethoxybenzoyloxy) hexyl] -6,7-dimethoxy- 7.0 g of colorless needles of 1,2,3,4-tetrahydro-2-naphthylamine hydrochloride were obtained.

Figure kpo00018
Figure kpo00018

[실시예 6]Example 6

N-에틸-1,2,3,4-테트라하이드로-2-나프틸아민염 1.86g, 3,4-산염디메톡시안식향산 6-클로로헥실에스테르 2.9g, 요드화나트륨 1.45g, 탄산나트륨 1.02g 및 메틸에틸케논 30ml를 사용하여 실시에 3(나)에 따라 행하고 N-에틸-N-[6-(3,4-디메톡시벤조일옥시)헥실]-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색유상물 1.0g을 얻었다.1.86 g of N-ethyl-1,2,3,4-tetrahydro-2-naphthylamine salt, 2.9 g of 3,4-acid dimethoxybenzoic acid 6-chlorohexyl ester, 1.45 g of sodium iodide, 1.02 g of sodium carbonate, and The procedure was carried out in accordance with Example 3 (b), using 30 ml of methyl ethyl kenone, and N-ethyl-N- [6- (3,4-dimethoxybenzoyloxy) hexyl] -1,2,3,4-tetrahydro-2 1.0 g of a colorless oil of naphthylamine hydrochloride was obtained.

Figure kpo00019
Figure kpo00019

[실시예 7]Example 7

N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 1.91g, 3,4-디메톡시안식 2-(2향산클로로에톡시)에틸에스테르 2.96g, 요드화나트륨 1.54g, 탄산나트륨 1.07g 및 메틸에틸케톤 30ml를 사용하여 실시예 3(나)에 표시한 방법에 따라 행하고 N-에틸-N-[2-(2-(3,4-디메톡시벤조일옥시)에틸]]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 유상물 1.6g을 얻었다.1.91 g of N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride, 2.96 g of 3,4-dimethoxybenzoyl (2-dichlorochloroethoxy) ethyl ester, 1.54 g of sodium iodide, 1.07 g of sodium carbonate and 30 ml of methyl ethyl ketone were carried out according to the method shown in Example 3 (b), followed by N-ethyl-N- [2- (2- (3,4-dimethoxybenzoyl). Oxy) ethyl]]-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride 1.6g was obtained.

Figure kpo00020
Figure kpo00020

[실시예 8]Example 8

6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 1.1g, 3,4-디메톡시안식향산 4-클로로부틸에스테르 1.1g, 요드화나트륨 1.0g, 탄산나트륨 1.0g 및 메틸에틸케논 30ml를 사용하여 실시예 3(나)에 표시한 방법에 따라 행하고 [-4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸민염산염의 무색판상정 0.3g을 얻는다.1.1 g of 6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride, 1.1 g of 3,4-dimethoxybenzoic acid 4-chlorobutyl ester, 1.0 g of sodium iodide, 1.0 g of sodium carbonate, and [00 (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4- was carried out according to the method shown in Example 3 (b) using 30 ml of methyl ethyl kenone. 0.3 g of colorless tablets of tetrahydro-2-naphthyl hydrochloride are obtained.

Figure kpo00021
Figure kpo00021

[실시예 9]Example 9

(가)P-에톡시페닐초산 5.0g, 5염화인 7.0g 및 무수벤젠 10ml를 혼합하여 80℃에서 두시간동안 가열한다. 반응액을 감압하에 농축하고 잔류물을 무수디클로로메탄 20ml에 용해하고 이용액을 -50℃에서 냉각한 무수염화알미늄 7.3g과 무수디클로로메탄 80ml의 혼합액중에 적가한다음 에틸렌가스를 20분간 격렬하게 이 속에 주입한다. 계속해서 실온에서 4시간동안 교반한다. 반응액을 빙냉하에 물 30ml를 적가한다. 디클로로메탄층을 분리취출해서 8% 염산물, 포화탄산수소나트륨수용액, 물 순서로 세척한다. 무수유산나트륨으로 건조한 후 감압하에 농축하면 6-에톡시-2-테트라론의 담황색 유상물로서 얻어진다. 이와 같이 하여 얻어진 6-에톡시-2-테트라론을 거칠게 제조한 그대로 20% 에틸아민에탄올 용액 40ml, 산화백금 0.4g과 함께 접촉환원을 행한다. 수소의 흡수가 끝난후 여과하여 촉매를 제거하고 여액을 감압하고 농축한다. 잔사를 클로로포름으로 추출하고 2N-수산화나트륨, 물순으로 세척하고 무수유산나트륨으로 건조한후 감압하여 농축한다. 잔사에 염화수소, 에탄올용액을 가하여 감압하에 농축한다. 석출한 결정을 에탄올, 에테르의 혼액으로부터 재결정하여 N-에틸-6-에톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색 침상정 1.4g을 얻는다.(A) 5.0 g of P-ethoxyphenyl acetate, 7.0 g of phosphorus pentachloride and 10 ml of anhydrous benzene are mixed and heated at 80 ° C. for 2 hours. The reaction solution was concentrated under reduced pressure, the residue was dissolved in 20 ml of anhydrous dichloromethane, and the used solution was added dropwise to a mixed solution of 7.3 g of anhydrous aluminum chloride and 80 ml of anhydrous dichloromethane cooled at -50 ° C, and ethylene gas was vigorously added thereto for 20 minutes. Inject. Then stir for 4 hours at room temperature. The reaction solution was added dropwise to 30 ml of water under ice cooling. The dichloromethane layer is separated out and washed with 8% hydrochloric acid, saturated aqueous sodium hydrogen carbonate solution and then water. After drying over anhydrous sodium sulfate and concentrating under reduced pressure, it is obtained as a pale yellow oil of 6-ethoxy-2-tetraron. Thus-reduced 6-ethoxy-2-tetraron was subjected to catalytic reduction with 40 ml of 20% ethylamine ethanol solution and 0.4 g of platinum oxide as it was roughly produced. After the absorption of hydrogen is over, the catalyst is removed by filtration, and the filtrate is depressurized and concentrated. The residue was extracted with chloroform, washed with 2N-sodium hydroxide and water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. Hydrogen chloride and ethanol solution were added to the residue, and concentrated under reduced pressure. The precipitated crystals are recrystallized from a mixture of ethanol and ether to obtain 1.4 g of colorless needles of N-ethyl-6-ethoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride.

Figure kpo00022
Figure kpo00022

(나)N-에틸-6-에톡시-1,2,3,4-테트라하이드로-2-나프틸아민산염 1.0g, 3,4-디메톡시안식향산 4-클로로부틸에스테르 1.2g, 요드화나트륨 1.0g, 탄산나트륨 1.0g 및 메틸에틸케톤 40ml를 하용하여 실시예 3(나)에 표시한 방법에 따라 행하고 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-에톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산의 무색결정 0.6g을 얻었다.(B) 1.0 g of N-ethyl-6-ethoxy-1,2,3,4-tetrahydro-2-naphthylamine acid salt, 1.2 g of 3,4-dimethoxybenzoic acid 4-chlorobutyl ester, sodium iodide N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6 was carried out according to the method shown in Example 3 (b) with 1.0 g, 1.0 g of sodium carbonate and 40 ml of methyl ethyl ketone. 0.6 g of colorless crystals of -ethoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloric acid were obtained.

Figure kpo00023
Figure kpo00023

[실시예 10]Example 10

(가)P-n-프로폭시페닐초산 5.0g을 사용하여 실시예 9(가)에 표시한 방법에 준하여 행하고 N-에틸-6-n-프로폭시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 1.1g을 얻는다.(A) N-ethyl-6-n-propoxy-1,2,3,4-tetrahydro-2 was carried out according to the method shown in Example 9 (A) using 5.0 g of Pn-propoxyphenylacetic acid. 1.1 g of colorless crystals of naphthylamine hydrochloride are obtained.

Figure kpo00024
Figure kpo00024

(나)N-에틸-6-n-프로폭시-1,2,3,4-테트라하이드로-2-나프틸아민산염 1.0g, 3,4-디메톡시안식향산 4-클로로 부틸에스테르 1.2g, 요드화나트륨 1.0g, 탄산나트륨 1.0g 및 메틸에틸케톤 40ml를 사용하여 실시예 3(나)에 표시한 방법에 준하여 N-에틸-N-[4-(3,4-디틸톡시벤조일옥시)부틸]-6-n-프로폭시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색침상정 0.7g를 얻는다.(B) 1.0 g of N-ethyl-6-n-propoxy-1,2,3,4-tetrahydro-2-naphthylamine acid salt, 1.2 g of 3,4-dimethoxybenzoic acid 4-chloro butyl ester, iodine N-ethyl-N- [4- (3,4-ditylmethoxybenzoyloxy) butyl]-according to the method shown in Example 3 (b) using 1.0 g of sodium sulfate, 1.0 g of sodium carbonate and 40 ml of methyl ethyl ketone. 0.7 g of colorless needles of 6-n-propoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00025
Figure kpo00025

[실시예 11]Example 11

(가)6-메톡시-2-테트라론 20g, 이소프로필아민 22g, 산화백금 0.5g, 무수에탄올 20ml를 사용하여 실시예 2(가)에 표시한 방법에 따라 행하고 N-이소프로필-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색침상정을 13.9g 얻는다.(A) 20 g of 6-methoxy-2-tetraron, 22 g of isopropylamine, 0.5 g of platinum oxide, and 20 ml of anhydrous ethanol were used in the same manner as described in Example 2 (a), and N-isopropyl-6- 13.9g of colorless needles of methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00026
Figure kpo00026

(나)N-이소프로필-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산염 1.6g, 3,4-디메톡시 4-안식향산요드화부틸에스테르 2.5g, 탄산나트륨 0.65g, 메틸케톤 40ml를 사용하여 실시예 2(나)에 표시한 방법에 따라 행하고 N-이소프로필-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 0.95g을 얻는다.(B) N-isopropyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine salt 1.6g, 3,4-dimethoxy 4-benzoic acid iodide butyl ester 2.5g, sodium carbonate N-isopropyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy- was carried out according to the method shown in Example 2 (b) using 0.65 g and 40 ml of methyl ketone. 0.95 g of colorless crystals of 1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00027
Figure kpo00027

[실시에 12][12]

(가)6-메톡시-2-테트라론 21.0g, n-프로필아민 22g, 산화백금 0.5g 및 무수에탄올 25ml를 사용하여 실시예 2(가)에 표시한 방법에 따라 행하고 N-n-프로필-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정을 25.0g을 얻는다.(A) N-propyl-6 was carried out according to the method shown in Example 2 (a) using 21.0 g of 6-methoxy-2-tetraron, 22 g of n-propylamine, 0.5 g of platinum oxide, and 25 ml of anhydrous ethanol. 25.0 g of colorless crystals of -methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00028
Figure kpo00028

(나)N-n-프로필-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산염 2.0g, 3,4-디메톡시안식향산 4-요드화부틸에스테르 3.15g, 탄산나트륨 1.9g 및 메틸에틸케톤 50ml를 사용하여 실시예 2(나)에 표시한 방법에 따라 N-n-프로필-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색유상물 2.35g을 얻는다.(B) Nn-propyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine acid salt 2.0g, 3,4-dimethoxybenzoic acid 4-iodide ester 3.15g, sodium carbonate 1.9 g and 50 ml of methyl ethyl ketone according to the method shown in Example 2 (b), Nn-propyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1, 2.35 g of a colorless oil of 2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00029
Figure kpo00029

[실시예 13]Example 13

N-메틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산염 2.0g,3,4-디메톡시안식향산 4-요드화부틸에스테르 3.3g, 탄산나트륨 2.1g 및 메틸에틸케톤 50ml를 사용하여 실시예 2(나)에 표시한 방법으로 행하고 N-메틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색유상물 1.9g를 얻는다.N-methyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthyl amine salt 2.0g, 3,4-dimethoxybenzoic acid 4-iod butyl ester 3.3g, sodium carbonate 2.1g and methyl N-methyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3 was carried out by the method shown in Example 2 (b) using 50 ml of ethyl ketone. 1.9 g of colorless oils of, 4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00030
Figure kpo00030

[실시예 14]Example 14

N-에틸-1,2,3,4-메톡시테트라하이드로-2-나프틸아민산염 2.0g, 3,4,5-트리메톡시안식향산 4-요드화부틸에스테르 3.3g, 탄산나트륨 0.9g 및 메틸에틸케톤 40ml를 사용하여 실시예 2(나)에 표시한 방법으로 얻어진 N-에틸-N-[4-(3,4,5-트리메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 유기염기를 메탄설포산과 처리하여 메탄설폰산염의 담황색유산물 1.5g을 얻는다.2.0 g of N-ethyl-1,2,3,4-methoxytetrahydro-2-naphthylamine acid salt, 3.3 g of 3,4,5-trimethoxybenzoic acid 4-iodine butyl ester, 0.9 g of sodium carbonate and methyl N-ethyl-N- [4- (3,4,5-trimethoxybenzoyloxy) butyl] -6-methoxy-1, obtained by the method shown in Example 2 (b) using 40 ml of ethyl ketone, The organic base of 2,3,4-tetrahydro-2-naphthylamine is treated with methanesulfonic acid to obtain 1.5 g of a pale yellow lactate of methanesulfonic acid salt.

Figure kpo00031
Figure kpo00031

[실시예 15]Example 15

N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산염 2.5g, 3,4-디메톡시안식향산-2-요드화에틸에스테르 3.6g, 탄산나트륨 1, 2g 및 메틸에틸케톤 40ml를 사용하여 실시예 2(나)에 표시한 방법에 따라 N-에틸-N-[2-(3,4-디메톡시벤조일옥시)에틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 2.9g을 얻는다.N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthyl amine salt 2.5g, 3,4-dimethoxybenzoic acid-2- iodide ethyl ester 3.6g, sodium carbonate 1, 2g And N-ethyl-N- [2- (3,4-dimethoxybenzoyloxy) ethyl] -6-methoxy-1,2 according to the method shown in Example 2 (b) using 40 ml of methyl ethyl ketone. 2.9 g of colorless crystals of, 3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00032
Figure kpo00032

[실시예 16]Example 16

N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염2.0,3,4-디메톡시안식향산-3-요드화프로필에스테르 3.4g, 탄산나트륨 1.2g 및 메틸에틸케톤 60ml를 사용하여 실시예 2(나)에 표시한 방법에 따라 N-에틸-N-[3-(3,4-디메톡시벤조일옥시)프로필]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 2.4g을 얻는다.N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride 2.0 g, 3,4-dimethoxybenzoic acid-3-iodide propyl ester 3.4 g, sodium carbonate 1.2 g and methyl N-ethyl-N- [3- (3,4-dimethoxybenzoyloxy) propyl] -6-methoxy-1,2,3 according to the method shown in Example 2 (b) using 60 ml of ethyl ketone. 2.4 g of colorless crystals of, 4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00033
Figure kpo00033

[실시예 17]Example 17

N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염2.1g, P-메톡시-안식향산 4-클로로부틸에스테르 3.2g, 요드화인나트륨 3.0g, 탄산나트륨 3.0g 및 메틸에틸케톤 60ml를 사용하여 실시예 2(나)에 표시한 방법에 따라 행하고 N-에틸-N-[4-(4-메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 1.34g을 얻는다.2.1 g of N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride, 3.2 g of P-methoxy-benzoic acid 4-chlorobutyl ester, 3.0 g of sodium iodide, sodium carbonate N-ethyl-N- [4- (4-methoxybenzoyloxy) butyl] -6-methoxy-1, carrying out the procedure as described in Example 2 (b) using 3.0 g and 60 ml of methyl ethyl ketone. 1.34 g of colorless crystals of 2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00034
Figure kpo00034

[실시예 18]Example 18

N-에틸-5,8-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 1.3g, 3,4-디메톡시안식향산 4-클로로부틸에스테르 1.8g, 요드화나트륨 0.9g, 탄산나트륨 0.8g 및 메틸 에틸케톤 80ml를 사용하여 실시예 3(나)에 표시한 방법에 따라 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-5,8-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 유상물 0.8g을 얻는다.1.3 g of N-ethyl-5,8-dimethoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride, 1.8 g of 3,4-dimethoxybenzoic acid 4-chlorobutyl ester, 0.9 g of sodium iodide g, 0.8 g sodium carbonate and 80 ml of methyl ethyl ketone according to the method shown in Example 3 (b), N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -5,8 0.8 g of an oil of dimethoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride is obtained.

Figure kpo00035
Figure kpo00035

또, 원료화합물 N-에틸-5,8-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산염의 합성법은 다음과 같다. 5,8-디메톡시-1-하이드록시-1,2,3,4-테트라하이드로-2-나프틸아민 0.7g, 15% 파라디움 0.3g, 78% 과염소산 0.5ml, 초산 30ml를 혼합하여 백열등을 조사하여 접촉 환원한다. 계산량의 수소흡수를 한후 촉매를 여과하고 여액에 초산칼륨 0, 5g을 하고 교반후 불용물을 여과하고 여액을 감압농축하고 잔류하는 0.7g 적갈색 엿형상물에 초산 10ml, 무수초산 2ml를 가하고 60℃의 수용중에서 두시간 가온하여 감압농축하고 디클로로메탄으로 추출하고 디클로로메탄층을 수세, 건조후 감압 건고하고 잔사를 아세톤-에테르로부터 재결정하고 N-아세틸-5,8-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산염 0.3g을 얻는다.In addition, the synthesis method of the raw material compound N-ethyl-5,8-dimethoxy-1,2,3,4-tetrahydro-2-naphthyl amine salt is as follows. 5,8-dimethoxy-1-hydroxy-1,2,3,4-tetrahydro-2-naphthylamine 0.7g, 15% paradium 0.3g, 78% perchloric acid 0.5ml, acetic acid 30ml mixed incandescent lamp It is irradiated and reduced by irradiation. After absorbing the calculated amount of hydrogen, the catalyst was filtered off, potassium acetate was added to the filtrate at 0, 5 g. After stirring, the insolubles were filtered out, the filtrate was concentrated under reduced pressure, and 10 ml of acetic acid and 2 ml of acetic anhydride were added to the remaining 0.7 g of reddish brown syrup. After warming in water for 2 hours, concentrated under reduced pressure, extracted with dichloromethane, washed dichloromethane layer with water, dried and dried under reduced pressure, and the residue was recrystallized from acetone-ether and N-acetyl-5,8-dimethoxy-1,2,3,4 0.3 g of tetrahydro-2-naphthyl amine salt is obtained.

Figure kpo00036
Figure kpo00036

수소화 리디움알므늄 1g을 테트라하이드로푸란 20ml에 현탁시켜 N-아세틸-5,8-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 2.0g을 테트라하이드로푸란 7ml에 용해한 용액을 적가한다. 적가후 2시간 30분동안 가열 환류시킨다. 빙냉후수 1.0ml-테트라히이드로푸란 10ml의 혼합액을 적가한다. 그후 15% 수산화나트륨 1ml, 물 3ml을 적가한다. 석출물을 여과하고 여액을 감압농축하고 클로로 포륨으로 추출하고 클로로포름층을 수세건조후 감압농축하고 잔사에 염화수소, 에탄올용액을 가하고 감압농축, 아세톤을 가하고 결정화한후 에탄올, 에테르로부터 재결정하고 N-에틸-5,8-디메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 1.3g을 얻는다. 융점 240 내지 242℃1 g of hydrogenated lithium almenium was suspended in 20 ml of tetrahydrofuran, and 2.0 g of N-acetyl-5,8-dimethoxy-1,2,3,4-tetrahydro-2-naphthylamine was dissolved in 7 ml of tetrahydrofuran. The solution is added dropwise. After the addition, the mixture was heated to reflux for 2 hours 30 minutes. A mixture of 1.0 ml of tetrahydrofuran and 10 ml of ice-cold water is added dropwise. Then 1 ml of 15% sodium hydroxide and 3 ml of water are added dropwise. The precipitate was filtered, the filtrate was concentrated under reduced pressure, extracted with chloroformium, and the chloroform layer was washed with water, and concentrated under reduced pressure. Hydrogen chloride and ethanol solution were added to the residue. 1.3 g of 5,8-dimethoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained. Melting point 240-242 ° C

[실시예 19]Example 19

N-에틸-5-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염2.1g,3,4-디메톡시안식향산-4-클로로부틸에스테르 3.2g, 요드화나트륨 3.0g, 탄산나트륨 3.0g 및 메틸에틸케톤 90ml를 사용하여 실시예 3(나)에 표시한 방법에 준하여 행하고 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-5-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 2.2g을 얻는다.N-ethyl-5-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride 2.1 g, 3,4-dimethoxybenzoic acid-4-chlorobutyl ester 3.2 g, sodium iodide 3.0 g N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -5-methism was carried out in accordance with the method shown in Example 3 (b) using 3.0 g of sodium carbonate and 90 ml of methyl ethyl ketone. 2.2 g of colorless crystals of oxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00037
Figure kpo00037

[실시예 20]Example 20

N-에틸-8-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산염2.4g, 3,4-디메톡시안식향산-4-클로로부틸에스테르 3.7g, 요드화나트륨 3.7g, 무수탄산나트륨 및 메틸에틸케톤 100ml를 사용하여 실시예 3(나)에 표시한 방법에 준하여 행하고 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-8-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 1.5g을 얻는다.N-ethyl-8-methoxy-1,2,3,4-tetrahydro-2-naphthyl amine salt 2.4g, 3,4-dimethoxybenzoic acid-4-chlorobutyl ester 3.7g, sodium iodide 3.7g , N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -8-methoxy using 100 ml of anhydrous sodium carbonate and methyl ethyl ketone according to the method shown in Example 3 (b) 1.5 g of colorless crystals of -1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00038
Figure kpo00038

[실시예 21]Example 21

N-에틸-8-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 3.5g, 3,4-디메톡시안식향산-6클로로헥실에스테르 6.2g, 요드화나트륨 3.1g, 탄산나트륨 2.2g, 메틸에틸케톤 100ml를 사용하여 실시예 3(나)에 표시한 방법에 따라 행하고 N-에틸-N-[6-(3,4-디메톡시벤조일옥시)헥실]-8-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 담황색 유상물 4.8g을 얻는다.3.5 g of N-ethyl-8-methoxy-1,2,3,4-tetrahydro-2-naphthylamine, 6.2 g of 3,4-dimethoxybenzoic acid-6chlorohexyl ester, 3.1 g of sodium iodide, sodium carbonate 2.2 g, 100 ml of methyl ethyl ketone was carried out according to the method shown in Example 3 (b), followed by N-ethyl-N- [6- (3,4-dimethoxybenzoyloxy) hexyl] -8-methoxy- 4.8 g of pale yellow oil of 1,2,3,4-tetrahydro-2-naphthylamine hydrochloride is obtained.

Figure kpo00039
Figure kpo00039

[실시예 22]Example 22

(가)7-메톡시-2-테트라론 12.4g, 19% 에틸아민에탄올용액 60ml 및 산화백금 0.4g를 사용하여 실시예 2(가)에 표시한 방법에 따라 행하고 N-에틸-7-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 10.7g을 얻는다.(A) 12.4 g of 7-methoxy-2-tetraron, 60 ml of 19% ethylamine ethanol solution and 0.4 g of platinum oxide were used in the same manner as described in Example 2 (A), and N-ethyl-7-meth 10.7 g of colorless crystals of oxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00040
Figure kpo00040

(나)N-에틸-7-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염2.0g, 3,4-디메톡시안식향산 4-요드화부틸에스테르 3.2g, 탄산나트륨 3.0g, 메틸에틸케톤 50ml를 사용하여 실시예 2(나)에 표시한 방법에 따라 행하고 N-에틸-N-N-[4-(3,4-디메톡시벤조일옥시)부틸]-7-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 1.2g을 얻는다.(B) N-ethyl-7-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride 2.0g, 3,4-dimethoxybenzoic acid 4-iodide ester 3.2g, sodium carbonate 3.0 g and 50 ml of methyl ethyl ketone were carried out according to the method shown in Example 2 (b), and N-ethyl-NN- [4- (3,4-dimethoxybenzoyloxy) butyl] -7-methoxy-1 1.2 g of colorless crystals of, 2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00041
Figure kpo00041

[실시예 23]Example 23

(가)6,7-메틸렌디옥시-2-테트라론 17.0g, 19% 에틸아민에탄올용액 120 ml, 산화백금 0.4g 및 무수에탄올 100ml을 사용하여 실시예 2(가)에 표시한 방법에 따라 행하고 N-에틸-6,7-메틸렌옥시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색침상정 7.2g을 얻는다.(A) Using 17.0 g of 6,7-methylenedioxy-2-tetraron, 120 ml of 19% ethylamine ethanol solution, 0.4 g of platinum oxide, and 100 ml of anhydrous ethanol, according to the method shown in Example 2 (A) 7.2 g of colorless needles of N-ethyl-6,7-methyleneoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00042
Figure kpo00042

(나)N-에틸-6,7-메틸렌디옥시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 2.0g, 3,4-디메톡시안식향산 4-클로로부틸에스테르 3.3g, 옥화나트륨 3.0g, 탄산나트륨 3.0g 및 메틸에틸케톤 40g를 사용하여 실시예 3(나)에 표시한 방법에 준하여 행하고 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6,7-메틸렌디옥시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색침상정 1.2g을 얻는다.(B) 2.0 g of N-ethyl-6,7-methylenedioxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride, 3.3 g of 3,4-dimethoxybenzoic acid 4-chlorobutyl ester, N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] was carried out in accordance with the method shown in Example 3 (b) using 3.0 g of sodium oxide, 3.0 g of sodium carbonate, and 40 g of methyl ethyl ketone. 1.2 g of colorless needles of -6,7-methylenedioxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00043
Figure kpo00043

[실시예 24]Example 24

(가)N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 8.8g, 트리에틸아민 6.1g 및 무수벤젠 80ml의 혼합액에 3-(메톡시카보닐)프로피오닐클로라이드 7.1g을 무수벤젠 10ml에 용해한 용액을 적가한다. 2시간 30분동안 가열하여 환류하 하루반 실온으로 방치한 반응액을 2N-염산, 물, 2N-수산화나트륨, 물의 순서로 세척하고 무수유산나트륨으로 건조한다. 감압하여 농축하여 N-에틸-N-[3-(메톡시카보닐)프로피오닐]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 담황색유형상물 12.5g을 얻는다.(A) 3- (methoxycarbonyl) into a mixture of 8.8 g of N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine, 6.1 g of triethylamine, and 80 ml of anhydrous benzene A solution of 7.1 g propionyl chloride dissolved in 10 ml of anhydrous benzene is added dropwise. After heating for 2 hours and 30 minutes, the reaction solution left at room temperature under reflux is washed in the order of 2N hydrochloric acid, water, 2N-sodium hydroxide and water, and dried over anhydrous sodium sulfate. Concentrate under reduced pressure to give 12.5 g of pale yellow color of N-ethyl-N- [3- (methoxycarbonyl) propionyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine. Get

(나)수소화리디움알미늄 8.3g을 무수테트라하이드로푸란 200ml에 현탁시킨다. 여기에 N-에틸-N-[3-(메톡시카보닐)프로피오닐]-6-메톡시-1,2,3,4-테트라히이드로-2-나프틸아민 14.5g과 무수 테트라하이드로푸란 100ml의 혼합액을 적가한다. 4.5시간 가열환류시킨 후 빙냉하에 물 8.3ml와 테트라하이드로푸란 50ml의 혼액을 적가한다. 다음에 15% 수산화나트륨 8.3ml을 적가하고 최후에 물 25ml를 적가한다. 석출한 불용물을 여과하여 제거하고 여액을 감압하에 농축한다. 잔사를 벤젠으로 추출하여 수세하고 무수유산나트륨으로 건조 후 감압하에 농축하면 N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 무색유상물 10.8g을 얻었다. 이와 같이 하여 얻은 유기염기를 염화수소, 에탄올용액으로 처리하여 염산염을 무색결정으로 하여 얻는다.(B) 8.3 g of lithium aluminum hydride is suspended in 200 ml of anhydrous tetrahydrofuran. Here, 14.5 g of N-ethyl-N- [3- (methoxycarbonyl) propionyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and anhydrous tetrahydrofuran 100 ml of the mixture is added dropwise. After refluxing for 4.5 hours, a mixture of 8.3 ml of water and 50 ml of tetrahydrofuran was added dropwise under ice-cooling. Then, 8.3 ml of 15% sodium hydroxide is added dropwise, and finally 25 ml of water is added dropwise. The precipitated insolubles are filtered off and the filtrate is concentrated under reduced pressure. The residue was extracted with benzene, washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2- 10.8 g of colorless oil (naphthylamine) was obtained. The organic base obtained in this manner is treated with hydrogen chloride and ethanol solution to obtain hydrochloride as colorless crystals.

Figure kpo00044
Figure kpo00044

(다)3,4-디메톡시안식향산 2.9g과 염화티오닐 4ml를 4시간동안 가열하고 환류한다. 감압하에 농축하여 얻어지는 3,4-디메톡시안식향산 클로라이드를 무수벤젠 10ml에 용해한 용액을 N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 4.0g, 트리에틸아민 2.2g 및 무수벤젠 50ml의 혼합액중에서 적가한다. 적가후 30분간 실온에서 교반한 후 3시간 30분동안 가열 환류한다. 반응액을 물, 2N-수산화나트륨, 물의 순서로 세척하고 무수유산나트륨으로 건조후 감압하에 농축한다. 잔사를 실리카겔컬럼 크로마토그라피로 정제하여 N-에틸-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 무색유상물을 얻었다. 이 유상물에 염화수소에탄올액을 가하고 감압하에 농축하고 잔사를 아세톤 에테르의 혼액과 저온에 방치하면 결정을 석출한다. 여과하고 모아서 아세톤, 에테르의 혼액과 저온에서 방치하면 결정을 석출한다. 여과하고 모아서 아세톤, 에테르의 혼액으로부터 재결정하여 N-에틸-N-[4 -(3,4-디메톡시벤조일옥시)부틸 ]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 3.0g을 얻는다. 융점 139 내지 140℃(C) 2.9 g of 3,4-dimethoxybenzoic acid and 4 ml of thionyl chloride are heated and refluxed for 4 hours. N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro was dissolved in 10 ml of anhydrous benzene with 3,4-dimethoxybenzoic acid chloride obtained by concentration under reduced pressure. It is added dropwise in a mixture of 4.0 g of 2-naphthylamine, 2.2 g of triethylamine and 50 ml of anhydrous benzene. After dropping, the mixture was stirred at room temperature for 30 minutes and then heated to reflux for 3 hours 30 minutes. The reaction solution is washed with water, 2N-sodium hydroxide and water in this order, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naph. A colorless oily product of tilamine was obtained. A hydrogen chloride ethanol solution is added to this oily substance, concentrated under reduced pressure, and the residue is left at a low temperature with a mixture of acetone ether to precipitate crystals. After filtration and collection, the mixture is left at low temperature with a mixture of acetone and ether to precipitate crystals. Filtration and collection recrystallized from a mixture of acetone and ether, and then N-ethyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2 3.0 g of colorless crystals of naphthylamine hydrochloride are obtained. Melting point 139 to 140

이 융점 및 적외스펙트럼등은 실시예 2(나)에서 얻어진 화합물의 것과 일치하였다.This melting point, infrared spectrum, and the like were consistent with those of the compound obtained in Example 2 (b).

[실시예 25]Example 25

(가)N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산 7.5g로부터 보통 때와 같이 행할 수 있는 유리염기와 5-(에톡시카보닐)펜타노일클로라이드 6.7g을 사용하여 실시예 24(가)에 표시한 방법에 따라 행하고 N-에틸-N-[5-(에톡시카르보닐)펜타노일]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 무색유상물 10.8g을 수득하였다.(A) N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride 7.5 g of free base and 5- (ethoxycarbonyl) which can be carried out as usual. N-ethyl-N- [5- (ethoxycarbonyl) pentanoyl] -6-methoxy-1,2,3 was carried out according to the method shown in Example 24 (A) using 6.7 g of pentanoyl chloride. 10.8 g of a colorless oil of, 4-tetrahydro-2-naphthylamine were obtained.

(나)N-에틸-N-[5-(에톡시카르보닐)펜타노일]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 10.8g 및 수소화리디움알미늄 4.5g을 사용하여 실시예 24(나)에 표시한 방법에 따라 행하고 N-에틸-N-[6-하이드록시헥실]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 담황색 유상물 8.2g을 얻는다.(B) 10.8 g of N-ethyl-N- [5- (ethoxycarbonyl) pentanoyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and lithium aluminum hydride 4.5 g was used according to the method shown in Example 24 (b) to prepare N-ethyl-N- [6-hydroxyhexyl] -6-methoxy-1,2,3,4-tetrahydro-2- 8.2 g of pale yellow oil of naphthylamine is obtained.

(다)3,4-디메톡시안식향산 5.2g으로부터 수득된 3,4-디메톡시안식향산 클로라이드와 N-에틸-N-(6-하이드록시헥실)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 8.2g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-[6-(3,4-디메톡시벤조일옥시)헥실]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 7.3g을 얻는다. 융점 119 내지 120℃. 이 융점 및 적외스펙트럼은 실시예 3(나)에서 얻어진 것과 동일하다.(C) 3,4-dimethoxybenzoic acid chloride obtained from 5.2 g of 3,4-dimethoxybenzoic acid and N-ethyl-N- (6-hydroxyhexyl) -6-methoxy-1,2,3,4 N-ethyl-N- [6- (3,4-dimethoxybenzoyloxy) hexyl] -6 was carried out according to the method shown in Example 24 (C) using 8.2 g of tetrahydro-2-naphthylamine. 7.3 g of colorless crystals of -methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained. Melting point 119 to 120 ° C. This melting point and infrared spectrum are the same as those obtained in Example 3 (b).

[실시에 26][Example 26]

(가)N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 3g 및 7-(에톡시카보닐)에 타노일클로라이드 2.9g을 사용하여 실시예 24(가)에 표시한 방법에 따라 행하고, N-에틸-N-[7-(에톡시카르보닐)헵타노일]-6-메톡시-1,2,3, 4-테트라하이드로-2-나프틸아민의 적갈색 유상물 4.6g을 얻는다.(A) Example using 3 g of N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride and 2.9 g of tanoyl chloride in 7- (ethoxycarbonyl) It carried out according to the method shown to 24 (a), N-ethyl-N- [7- (ethoxycarbonyl) heptanoyl] -6-methoxy-1,2,3,4-tetrahydro-2-naph 4.6 g of a reddish brown oil of tilamine is obtained.

(나)N-에틸-N-[7-(에톡시카보닐)헵타노일]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산 4.6g, 수소화리듐알미늄 2.0g을 사용하여 실시예 24(나)에 표시한 방법에 따라 행한다. N-에틸-N-(8-하이드록시옥틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 무색유상물 3.4g을 얻는다.(B) N-ethyl-N- [7- (ethoxycarbonyl) heptanoyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine acid 4.6 g, lithium aluminum hydride It carries out according to the method shown in Example 24 (b) using 2.0g. 3.4 g of a colorless oil of N-ethyl-N- (8-hydroxyoctyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine are obtained.

(다)N-에틸-N-(8-하이드록시옥틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 3.4g, 3,4-디메톡시벤조산 2.05g를 사용하여 실시예 24(다)의 방법에 따라 행한다. N-에틸-N-(8-(3,4-디메톡시벤조일옥시)옥틸)-6-메톡시-1,2, 3,4-테트라하이드로-2-나프틸아민염산염의 담황색 유상물 3.5g을 얻는다.(C) 3.4 g of N-ethyl-N- (8-hydroxyoctyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine, 2.05 g of 3,4-dimethoxybenzoic acid Using the method of Example 24 (C). 3.5 g pale yellow oil of N-ethyl-N- (8- (3,4-dimethoxybenzoyloxy) octyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride Get

Figure kpo00045
Figure kpo00045

[실시예 27]Example 27

(가)N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 염산염 6.11g 및 9-(에톡시카보닐)노나이소일클로라이드7.1g을 사용하여 실시예 24(가)에 표시한 방법에 따라 행하고 N-에틸-N-[9- (에톡시카보닐) 노다이노일]-6-메톡시 -1,2,3,4-테트라하이드로-2-나프틸아민의 담황색 유상물 11.4g을 얻는다.(A) using 6.11 g of N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride and 7.1 g of 9- (ethoxycarbonyl) nonisoyl chloride N-ethyl-N- [9- (ethoxycarbonyl) nodinoyl] -6-methoxy-1,2,3,4-tetrahydro-2- was carried out according to the method shown in Example 24 (A). 11.4 g of a pale yellow oil of naphthylamine is obtained.

(나)N-에틸-N-[9-(에톡시카보닐)노나노일]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민산 11.4g 및 소수화리디움알미늄 5.2g을 사용하여 실시예 24(가)에 표시한 방법에 따라 행하고 N-에틸-N- (10-하이드록시데실)- 6- 메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 유상물 9.3g을 얻는다.(B) 11.4 g of N-ethyl-N- [9- (ethoxycarbonyl) nonanoyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine acid and hydrophobicity Was carried out according to the method shown in Example 24 (A) using 5.2 g of dium aluminum, and N-ethyl-N- (10-hydroxydecyl) -6-methoxy-1,2,3,4-tetrahydro- 9.3 g of oil of 2-naphthylamine are obtained.

(다)N-에틸-N-(10-하이드록시데실)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 9.3g 및 3,4-디메톡시안식향산 5.17g를 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-[10-(3,4-디메톡시벤조일옥시)데실)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 유상물 8.8g을 얻는다.(C) 9.3 g of N-ethyl-N- (10-hydroxydecyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and 5.17 g of 3,4-dimethoxybenzoic acid N-ethyl-N- [10- (3,4-dimethoxybenzoyloxy) decyl) -6-methoxy-1,2,3,4 according to the method shown in Example 24 (C) using 8.8 g of an oil of tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00046
Figure kpo00046

[실시예 28]Example 28

(가)N-에틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸-아민염산염 0.6g 및 2-(에톡시카보닐)-2-메틸프로피오닐클로라이드 0.5g을 사용하여 실시예 24(가)에 표시한 방법에 준하여 행하고 N-에틸-N-[2-(에톡시카보닐)-2-메틸프로피오닐]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 유상물 0.68g을 얻는다.(A) 0.6 g of N-ethyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthyl-amine hydrochloride and 0.5 g of 2- (ethoxycarbonyl) -2-methylpropionyl chloride N-ethyl-N- [2- (ethoxycarbonyl) -2-methylpropionyl] -6-methoxy-1,2,3, which was prepared according to the method shown in Example 24 (a) using 0.68 g of an oil of 4-tetrahydro-2-naphthylamine is obtained.

(나)N-에틸-N-[2-(에톡시카보닐)-2-메틸프로피오닐]-6-메톡시-1,2,3 ,4-테트라하이드로-2-나프틸아민 0.66g, 수소화리티움알미늄 0.55g을 사용하여 실시예 24(나)에 표시한 방법에 따라 행하고, N-에톡시-N-(3-하이드록시-2,2-디메틸프로필-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 무색유상물 0.5g을 얻는다.(B) N-ethyl-N- [2- (ethoxycarbonyl) -2-methylpropionyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine 0.66 g, It was carried out according to the method shown in Example 24 (b) using 0.55 g of hydrium aluminum hydride, and N-ethoxy-N- (3-hydroxy-2,2-dimethylpropyl-6-methoxy-1, 0.5 g of a colorless oil of 2,3,4-tetrahydro-2-naphthylamine is obtained.

(다)N-에틸-N-(3-하이드록시-2,2-디메틸프로필)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸을 아민 0.45g 및 3,4-디메톡시안식향산 0.3g을 사용하여 실시예 24(다)에 표시한 방법에 준하여 행하고 N-에틸-N-[3-(3,4-디메톡시벤조일옥시)-2,2-디메틸-프로필]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 0.2g을 얻는다.(C) N-ethyl-N- (3-hydroxy-2,2-dimethylpropyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthyl 0.45 g and 3, N-ethyl-N- [3- (3,4-dimethoxybenzoyloxy) -2,2-dimethyl-propyl was carried out according to the method shown in Example 24 (C) using 0.3 g of 4-dimethoxybenzoic acid. 0.2 g of colorless crystals of] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00047
Figure kpo00047

[실시예 29]Example 29

(가)N-이소프로필-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 13.8g 및 3-(메톡시카보닐)프로피오닐클로라이드 9.1g을 사용하여 실시예 24(가)에 표시한 방법에 따라 행하고 N-이소프로필-N-[3-메톡시카보닐)프로피오닐]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 유상물 17.5g을 얻는다.(A) 13.8 g of N-isopropyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride and 9.1 g of 3- (methoxycarbonyl) propionyl chloride N-isopropyl-N- [3-methoxycarbonyl) propionyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphth, carried out according to the method shown in Example 24 (a). 17.5 g of oil of tilamine is obtained.

(나)N-이소프로필-N-[3-(메톡시카보닐)프로피오닐]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 17.5g 및 수소화리디움알미늄 7.2g을 사용하여 실시예 24(나)에 표시한 방법에 따라 행하고 N-이소프로필-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 유상물 12.85g을얻는다.(B) 17.5 g of N-isopropyl-N- [3- (methoxycarbonyl) propionyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and lithium hydride Performing according to the method shown in Example 24 (b) using 7.2 g of aluminum, and followed by N-isopropyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro- 12.85 g of an oil of 2-naphthylamine are obtained.

(다)N-이소프로필-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸-아민염산염 12.85g 및 3,4-디메톡시안식향산 8.12g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-이소프로필 -N-[4-(3,4- 디메 톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색침상정 16.2g을 얻는다. 융점 172 내지 174℃. 이 얻어진 것의 융점 및 적외스펙트럼은 어느 것이나 다 실시예 11(나)로 얻어진 것과 일치하였다.(C) 12.85 g of N-isopropyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthyl-amine hydrochloride and 3,4-dimethoxy N-isopropyl-N- [4- (3,4-dimethoxy-1,2,3,4-tetrahydro-2- was carried out according to the method shown in Example 24 (C) using 8.12 g of benzoic acid. Obtained 16.2 g of colorless needles of naphthylamine hydrochloride Melting point 172-174 DEG C. The melting point and infrared spectrum of this obtained were consistent with those obtained in Example 11 (b).

[실시예 30]Example 30

(가)N-n-프로필-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 15g 및 3-(메톡시카보닐)프로피오닐클로라이드 9.7g을 사용하여 실시예 24(가)에 표시한 방법에 따라 행하고 N-n-프로필-N-[3-(메톡시카보닐)프로피오닐]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 유상물 19.9g을 얻는다.Example 24 using 15 g of (n) Nn-propyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride and 9.7 g of 3- (methoxycarbonyl) propionyl chloride Nn-propyl-N- [3- (methoxycarbonyl) propionyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine was carried out according to the method (a). 19.9 g of oil is obtained.

(나)N-n-프로필-N-[3-(메톡시카보닐)프로피오닐]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 19.8g 및 수소화리디움 10g을 사용하여 실시예 24(나)에 표시한 방법에 따라 행하고 N-n-프로필-N-(4-하이드 록시부틸)-6- 메톡 시-1,2,3,4-테트라하이드로-2-나프틸아민의 유상물 13.5g을 얻는다.(B) 19.8 g of Nn-propyl-N- [3- (methoxycarbonyl) propionyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and 10 g of lithium hydride Nn-propyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthyl was carried out according to the method shown in Example 24 (b) using 13.5 g of an oil of amine is obtained.

(다)N-n-프로필-N-(4-(하이드록시부틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 13.45g 및 3,4-디메톡시안식향산 8.5g을 사용하여 N-n-프로필-N-[4-(3,4-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색엿형상물 19.0g을 얻는다. 이것은 적외스펙트럼은 실시예 12(나)에서 얻어진 것과 일치하였다.(C) 13.45 g of Nn-propyl-N- (4- (hydroxybutyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and 8.5 g of 3,4-dimethoxybenzoic acid Colorless syrup of Nn-propyl-N- [4- (3,4-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride using 19.0 g of the product is obtained, which is consistent with the infrared spectrum obtained in Example 12 (b).

[실시예 31]Example 31

(가)6-메톡시-2-테트라론 5.3g, 사이클로헥실아민 3g 및 무수에탄올 70ml를 7시간 가열시켜 환류한다. 여기에 산화백금 0.3g을 가하고 접촉환원을 행하고 수소가스의 흡수가 끝난후 촉매를 여별하고 여액을 감압농축하고 염화수소포화에탄올용액을 가하여 감압하에 농축한다. 잔사에 아세톤을 가하여 교반하고 석출한 결정을 여집하고 에탄올, 에테르의 혼액으로부터 재결정을 행하고 N-사이클로헥실-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색침상정 5.0g을 얻는다.5.3 g of (a) 6-methoxy-2-tetraron, 3 g of cyclohexylamine, and 70 ml of anhydrous ethanol were heated to reflux for 7 hours. 0.3 g of platinum oxide is added thereto, catalytic reduction is carried out. After the absorption of hydrogen gas is completed, the catalyst is filtered off, the filtrate is concentrated under reduced pressure, and a saturated hydrogen chloride ethanol solution is added and concentrated under reduced pressure. Acetone was added to the residue, followed by stirring. The precipitated crystals were collected and recrystallized from a mixture of ethanol and ether. 5.0 g of colorless needles are obtained.

Figure kpo00048
Figure kpo00048

(나)N-사이클로헥실-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염 5.0g 및 3-(메톡시카보닐)프로피오닐클로라이드 2.8g을 사용하여 실시예 24(가)에 표시한 방법에 따라 행하고 N-사이클로헥실-N-[3-(메톡시카보닐)프로피오닐]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 적갈색 유상물 3.5g을 얻는다.(B) 5.0 g of N-cyclohexyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride and 2.8 g of 3- (methoxycarbonyl) propionyl chloride N-cyclohexyl-N- [3- (methoxycarbonyl) propionyl] -6-methoxy-1,2,3,4-tetrahydro-2- was carried out according to the method shown in Example 24 (A). 3.5 g of reddish brown oil of naphthylamine is obtained.

(다)N-사이클로헥실-N-[3-(메톡시카보닐)프로피오닐]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 1.87g 수소화리디움알미늄 0.95g을 사용하여 실시예 24(나)에 표시한 방법에 따라 행하고 N-사이클로헥실-N-(4-(하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민의 황색유상물 1.45g을 얻는다.(C) N-cyclohexyl-N- [3- (methoxycarbonyl) propionyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine 1.87 g lithium aluminum hydride N-cyclohexyl-N- (4- (hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro- was carried out according to the method shown in Example 24 (b) using 0.95 g. 1.45 g of a yellow oil of 2-naphthylamine is obtained.

(라)N-사이클로헥실-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 2.8g 및 3,4-디메톡시안식향산 2.0g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-사이클로헥실-N-4-(3,4-디메톡시벤조일옥시)-부틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 담황색 유상물 2.6g을 얻는다.(D) N-cyclohexyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine 2.8 g and 3,4-dimethoxybenzoic acid 2.0 N-cyclohexyl-N-4- (3,4-dimethoxybenzoyloxy) -butyl-6-methoxy-1,2,3, which was prepared according to the method shown in Example 24 (C) using g. 2.6 g of pale yellow oil of 4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00049
Figure kpo00049

[실시예 32]Example 32

N-에틸-N-(4-하이드록시부틸-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 0.2g 및 안식향산클로라이드 0.16g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-(4-벤조일옥시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 0.07g을 얻는다.Example 24 (C) using 0.2 g of N-ethyl-N- (4-hydroxybutyl-6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and 0.16 g of benzoic acid chloride 0.07 g of colorless crystals of N-ethyl-N- (4-benzoyloxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride are obtained by following the method shown in .

Figure kpo00050
Figure kpo00050

[실시예 33]Example 33

N-에틸 -N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 1.4g 및 피페로닐산 1.0g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-[4-(3,4-메틸렌옥시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 0.82g을 얻는다.Example 24 (using 1.4 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and 1.0 g of piperonic acid) C) N-ethyl-N- [4- (3,4-methyleneoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naph 0.82 g of colorless crystals of tilamine hydrochloride are obtained.

Figure kpo00051
Figure kpo00051

[실시예 34]Example 34

N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라-하이드로-2 -나프틸아민 1.5g 및 2,6-디메톡시안식향산 1.0g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-[4-2,6-디메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 유상물 0.55g을 얻는다.1.5 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetra-hydro-2-naphthylamine and 1.0 g of 2,6-dimethoxybenzoic acid are used N-ethyl-N- [4-2,6-dimethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro was carried out according to the method shown in Example 24 (C). 0.55 g of an oil of 2-naphthylamine hydrochloride is obtained.

Figure kpo00052
Figure kpo00052

[실시예 35]Example 35

N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 0.2g 및 P-에톡시안식향산 0.132g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-[4-(에톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 0.18g을 얻는다.Example using 0.2 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and 0.132 g of P-ethoxybenzoic acid N-ethyl-N- [4- (ethoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine was carried out according to the method shown in 24 (C). 0.18 g of colorless crystals of hydrochloride are obtained.

Figure kpo00053
Figure kpo00053

[실시예 36]Example 36

N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 0.2g 및 P-n-프로폭시안식향산 0.15g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-[4-(4-n-프로폭시벤조일옥시) 부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색결정 0.23g을 얻었다.Example using 0.2 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and 0.15 g of Pn-propoxycyanic acid N-ethyl-N- [4- (4-n-propoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2 was carried out according to the method shown in 24 (C). 0.23 g of colorless crystals of naphthylamine hydrochloride were obtained.

Figure kpo00054
Figure kpo00054

[실시예 37]Example 37

N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 0.2g, 3,4,5-트리에톡시향산 0.2g을 사용하여 실시예 24(다)에 표시한 방법에 준하여 행하고 N-에틸-N-[4-(3,4,5-트리에톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 염산염의 유상물 0.2g을 얻었다.0.2 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine, 0.2 g of 3,4,5-triethoxy aromatic acid N-ethyl-N- [4- (3,4,5-triethoxybenzoyloxy) butyl] -6-methoxy-1,2, which was prepared according to the method shown in Example 24 (C) using 0.2 g of an oily product of 3,4-tetrahydro-2-naphthylamine hydrochloride was obtained.

Figure kpo00055
Figure kpo00055

[실시예 38]Example 38

N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 0.28g, 3-메톡시-4-에톡시안식향산 0.22g을 사용하여 실시예 24(다)에 표시한 방법에 준하여 행하고 N-에틸-N-[4-(3-메톡시-4-에톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색유상물 0.2g을 얻었다.0.28 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine, 0.22 g of 3-methoxy-4-ethoxybenzoic acid N-ethyl-N- [4- (3-methoxy-4-ethoxybenzoyloxy) butyl] -6-methoxy-1,2, which was prepared according to the method shown in Example 24 (C) using 0.2 g of colorless oils of 3,4-tetrahydro-2-naphthylamine hydrochloride were obtained.

Figure kpo00056
Figure kpo00056

[실시예 39]Example 39

m-메톡시안식향산 0.9g, N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2, 3,4-테트라하이드로-2-나프틸아민 1.5g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-[4-(3-메톡시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 염산염의 무색분말 0.85g을 얻는다.Example using 0.9 g of m-methoxybenzoic acid and 1.5 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine N-ethyl-N- [4- (3-methoxybenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naph was carried out according to the method shown in 24 (C). 0.85 g of a colorless powder of tilamine hydrochloride is obtained.

Figure kpo00057
Figure kpo00057

[실시예 40]Example 40

P-톨루일산 0.8g, N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 1.5g을 사용하여 실시예 24(다)에 표시한 방법에 준하여 행하고 N-에틸-N-[4-(4-메틸벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염의 무색분말 1.15g을 얻는다.Example 24 using 0.8 g of P-toluic acid and 1.5 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine N-ethyl-N- [4- (4-methylbenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine was carried out according to the method described in (C). 1.15 g of colorless powder of hydrochloride are obtained.

Figure kpo00058
Figure kpo00058

[실시예 41]Example 41

N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 2.0g 및 3,4-디클로로안식향산 클로라이드 1.7g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-[4-(3,4-디클로로벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 염산염의 무색침상정 1.5g을 얻는다.Using 2.0 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and 1.7 g of 3,4-dichlorobenzoic acid chloride N-ethyl-N- [4- (3,4-dichlorobenzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro- was carried out according to the method shown in Example 24 (C). 1.5 g of colorless needles of 2-naphthylamine hydrochloride are obtained.

Figure kpo00059
Figure kpo00059

[실시예 42]Example 42

N-에틸-N-(4-하이드록시부틸)-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 2.0g 및 3,4-비스(벤질옥시)안식향산 2.5g을 사용하여 실시예 24(다)에 표시한 방법에 따라 행하고 N-에틸-N-[4-(3,4-비스(벤질옥시)벤조일옥시부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민 염산염의 무색분말 3.0g을 얻는다.2.0 g of N-ethyl-N- (4-hydroxybutyl) -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine and 2.5 g of 3,4-bis (benzyloxy) benzoic acid N-ethyl-N- [4- (3,4-bis (benzyloxy) benzoyloxybutyl] -6-methoxy-1,2,3 using the method shown in Example 24 (C) using 3.0 g of a colorless powder of, 4-tetrahydro-2-naphthylamine hydrochloride are obtained.

Figure kpo00060
Figure kpo00060

N-에틸-N-[4-(3,4-비스(벤질옥시)벤조일옥시)부틸]-6-메톡시-1,2,3 ,4-테트라하이드로-2-나프틸아민염산염 2.5g, 물 70ml, 에탄올 70ml와 5% 파라디움탄소 0.5g을 마겐속에 혼합상은, 상압하에 접촉환원을 행한다.2.5 g of N-ethyl-N- [4- (3,4-bis (benzyloxy) benzoyloxy) butyl] -6-methoxy-1,2,3,4-tetrahydro-2-naphthylamine hydrochloride, 70 ml of water, 70 ml of ethanol, and 0.5 g of 5% palladium carbon were mixed with magenta in a reduced phase under normal pressure.

계산량의 수소를 흡수후 촉매를 여과하여 제거하고 여액을 감압하여 농축하면 N-에틸-N-[4-(3,4-디하이드록시벤조일옥시)부틸]-6-메톡시-1,2,3,4-테트라하이드로-2-나프틸아민염산염을 무색엿형상물로서 1.5g을 얻는다.After absorbing the calculated amount of hydrogen, the catalyst was filtered off, and the filtrate was concentrated under reduced pressure. N-ethyl-N- [4- (3,4-dihydroxybenzoyloxy) butyl] -6-methoxy-1,2, 1.5 g of 3,4-tetrahydro-2-naphthylamine hydrochloride is obtained as a colorless syrup.

Figure kpo00061
Figure kpo00061

Claims (1)

다음 구조식(II)의 화합물을 다음 구조식(III)의 화합물로 반응시켜 다음 구조식(I)의 2-아미노테트라린 유도체를 제조하는 방법.A method for preparing the 2-aminotetrarin derivative of the following formula (I) by reacting a compound of the following formula (II) with a compound of the following formula (III).
Figure kpo00062
Figure kpo00062
상기 구조식에서In the above structural formula R1및 R2는 같거나 다른 수소원자, 저급알콕시기 또는 두개가 함께 결합하여 저급알킬렌 디옥시기를 나타내며, R3은 수소원자, 저급알킬기 또는 사이클로알킬기를 나타내며, R4, R5, R6는 같거나 다른 수소원자, 저급알콕시기, 저급알킬기, 할로겐기, 수산기 또는 두개가 함께 결합하여 저급알킬렌 디옥시기를 나타내며, A는 직쇄 또는 측쇄의 탄소수 2 내지 10개를 갖는 알킬렌기 또는 중간에 산소원자로 에테르결합을 갖는 알킬렌기를 나타내며, X는 할로겐원자를 나타낸다(단 구조식(III)에 있어서 R4, R5, R6의 수산기는 보호기로 보호시킨다음 반응후 보호기를 유리한다).R 1 and R 2 represent the same or different hydrogen atoms, lower alkoxy groups or two together to represent a lower alkylene dioxy group, R 3 represents a hydrogen atom, a lower alkyl group or a cycloalkyl group, and R 4 , R 5 , R 6 represents the same or different hydrogen atom, lower alkoxy group, lower alkyl group, halogen group, hydroxyl group or two together to represent a lower alkylene dioxy group, A is an alkylene group having 2 to 10 carbon atoms or straight or branched chain or intermediate Represents an alkylene group having an ether bond as an oxygen atom, and X represents a halogen atom (however, in the formula (III), the hydroxyl groups of R 4 , R 5 , and R 6 are protected by a protecting group, and then a protecting group is advantageous after the reaction).
KR7803463A 1978-11-17 1978-11-17 Process for producing of 2-amino tetralin derivatives Expired KR810001299B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7803463A KR810001299B1 (en) 1978-11-17 1978-11-17 Process for producing of 2-amino tetralin derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7803463A KR810001299B1 (en) 1978-11-17 1978-11-17 Process for producing of 2-amino tetralin derivatives

Publications (1)

Publication Number Publication Date
KR810001299B1 true KR810001299B1 (en) 1981-10-13

Family

ID=19209205

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7803463A Expired KR810001299B1 (en) 1978-11-17 1978-11-17 Process for producing of 2-amino tetralin derivatives

Country Status (1)

Country Link
KR (1) KR810001299B1 (en)

Similar Documents

Publication Publication Date Title
ES2273413T3 (en) TRICYCLE COMPOUNDS.
FI57417C (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ANALYZED 2-SUBSTITUTES-OXAZOLO- (4,5-B) -PYRIDINER
DE3418270A1 (en) NEW AMINOTETRAL DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
EP0286278B1 (en) Indanamine derivatives useful as antiarrhythmic agents
JP2502343B2 (en) A pharmaceutically active substituted benzamide
US5094782A (en) Synthesis of capsacin derivatives and their use as an analgesic drug and vessel dilation drug
US8431591B2 (en) R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof
TW589305B (en) 4-aminobenzopyran derivatives
HU185133B (en) Process for producing 1-hydroxy-octahydro-benzo-bracket-c-bracket closed-quinolines and derivatives
DE69411589T2 (en) INDOL, INDOLIN AND CHINOLIN DERIVATIVES WITH A 5HT1D ANTAGONISTIC EFFECT
CN111574533A (en) Ring-opening aminated derivative of limonin A or its pharmaceutically acceptable salt, preparation method and use
EP0283761A1 (en) Chromone derivatives
EP0481383A1 (en) Heterocyclic amine derivatives, their production and use
US4239903A (en) 2-Aminotetralin derivatives and process for producing the same
US3272827A (en) Alpha-phenyl-beta-(2-furyl propionitrile compounds and a process of making same
CN113087713A (en) Benzodiazepine derivatives, and preparation method and use thereof
KR0181945B1 (en) N,n'-bis(alkoxy)-pyridine-2,4-dicarboxylic acid diamines
KR810001299B1 (en) Process for producing of 2-amino tetralin derivatives
PT91555B (en) METHOD FOR PREPARING DIBENZO (2,3,6,7) - (OXEPINO OR TIEPINO) {4,5-C} (PYRIDINE OR PYRROLE) DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN114149386A (en) Aryl pentadiene amide aldehyde dehydrogenase inhibitor, and synthesis method and application thereof
EP0538477B1 (en) Novel cyclic aminophenylacetic acid derivative, production thereof, and immune response modulator containing the same as active ingredient
JP2000136173A (en) New cyclic compound having cycloalkylene chain, production thereof and pharmaceutical composition containing the same compound
JPS6399057A (en) Glycine derivative
SU1036249A3 (en) Process for preparing derivatives of 5,6,8,9-tetrahydro-7h-dibenz-(d,f)-azonine or their salts
KR20010074498A (en) Bioreductive cytotoxic agents

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19781117

PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19810905

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19811221

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19820106

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19850822

End annual number: 5

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19860904

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 19870901

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 19880829

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 19890829

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 19900731

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 19910819

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 19920813

Start annual number: 12

End annual number: 12

PC1801 Expiration of term